

# Antonio Bertolotto

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5770827/antonio-bertolotto-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

251  
papers

10,598  
citations

53  
h-index

95  
g-index

262  
ext. papers

11,835  
ext. citations

5.3  
avg, IF

5.6  
L-index

#	Paper	IF	Citations
251	The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of NR4A Genes in Microglia Cell Line. <i>Current Issues in Molecular Biology</i> , <b>2022</b> , 44, 1247-1256	2.9	0
250	The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes.. <i>Molecular Biology Reports</i> , <b>2022</b> , 1	2.8	
249	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. <i>Neurology</i> , <b>2022</b> , 98, e1626-e1636	6.5	0
248	Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 775151	8.4	0
247	Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report. <i>Neurological Sciences</i> , <b>2021</b> , 42, 25-28	3.5	1
246	Exposure to fine particulate matter (PM) hampers myelin repair in a mouse model of white matter demyelination. <i>Neurochemistry International</i> , <b>2021</b> , 145, 104991	4.4	1
245	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	3
244	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2021</b> , 78, 726-735	17.2	4
243	Coverage of the requirements of first and second level stroke unit in Italy. <i>Neurological Sciences</i> , <b>2021</b> , 42, 1073-1079	3.5	1
242	Overexpression of the ubiquitin-editing enzyme A20 in the brain lesions of Multiple Sclerosis patients: moving from systemic to central nervous system inflammation. <i>Brain Pathology</i> , <b>2021</b> , 31, 283-296	6	4
241	Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 567-578	6	4
240	Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> ,	6.5	11
239	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2021</b> , 89, 780-789	9.4	189
238	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. <i>Health and Quality of Life Outcomes</i> , <b>2021</b> , 19, 224	3	
237	Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 54, 103090	4	2
236	Successful pregnancy and disease outcomes in a NMOSD patient treated with tocilizumab. <i>Neuroimmunology Reports</i> , <b>2021</b> , 1, 100014		0
235	Analysis of the Gadolinium retention in the Experimental Autoimmune Encephalomyelitis (EAE) murine model of Multiple Sclerosis. <i>Journal of Trace Elements in Medicine and Biology</i> , <b>2021</b> , 68, 126831	4.1	2

234	Validation of an Algorithm to Detect Multiple Sclerosis Cases in Administrative Health Databases in Piedmont (Italy): An Application to the Estimate of Prevalence by Age and Urbanization Level. <i>Neuroepidemiology</i> , <b>2021</b> , 55, 119-125	5.4	1
233	Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 46, 102592	4	2
232	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , <b>2020</b> , 9, 443-457	4.6	4
231	Concomitant brain arterial and venous thrombosis in a COVID-19 patient. <i>European Journal of Neurology</i> , <b>2020</b> , 27, e38-e39	6	22
230	Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients. <i>Neurology and Therapy</i> , <b>2020</b> , 9, 197-203	4.6	7
229	In vivo silencing of miR-125a-3p promotes myelin repair in models of white matter demyelination. <i>Glia</i> , <b>2020</b> , 68, 2001-2014	9	14
228	TNFAIP3 Deficiency Affects Monocytes, Monocytes-Derived Cells and Microglia in Mice. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
227	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. <i>Neurological Sciences</i> , <b>2020</b> , 41, 2843-2851	3.5	4
226	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2020</b> , 6, 2055217320972137	2	2
225	Assessing measurement invariance of MSQOL-54 across Italian and English versions. <i>Quality of Life Research</i> , <b>2020</b> , 29, 783-791	3.7	2
224	The reliability of objective fatigue measures in Multiple Sclerosis Patients. <i>Biomedical Signal Processing and Control</i> , <b>2020</b> , 56, 101696	4.9	0
223	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 445-453	6	9
222	The transcription factor Nurr1 is upregulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice. <i>DMM Disease Models and Mechanisms</i> , <b>2020</b> , 13,	4.1	4
221	NURR1 deficiency is associated to ADHD-like phenotypes in mice. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 207	8.6	11
220	Immunomodulatory Effect of Pregnancy on Leukocyte Populations in Patients With Multiple Sclerosis: A Comparison of Peripheral Blood and Decidual Placental Tissue. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1935	8.4	10
219	NURR1 Impairment in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	9
218	Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 253	4.1	12
217	Neurology and Therapy: Looking Back on 2018 and Forward to 2019. <i>Neurology and Therapy</i> , <b>2019</b> , 8, 1-3	4.6	

216	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 856-866	5	5
215	The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. <i>Global &amp; Regional Health Technology Assessment</i> , <b>2019</b> , 2019, 228424031983852	0.2	1
214	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 695	4.1	3
213	Acknowledgement to Authors, Referees and Readers 2019. <i>Neurology and Therapy</i> , <b>2019</b> , 8, 513-515	4.6	
212	Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod. <i>European Journal of Neurology</i> , <b>2019</b> , 26, 667-672	6	5
211	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 399-407	5	20
210	Prevalence of Posttraumatic Stress Disorder in Patients With Multiple Sclerosis. <i>Journal of Nervous and Mental Disease</i> , <b>2018</b> , 206, 149-151	1.8	6
209	The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto's Thyroiditis. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 311	8.4	14
208	Access to social security benefits among multiple sclerosis patients in Italy: A cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 24, 107-112	4	1
207	Acknowledgement to Authors, Referees, and Readers. <i>Neurology and Therapy</i> , <b>2018</b> , 7, 395-396	4.6	78
206	Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl. <i>Neurology and Therapy</i> , <b>2018</b> , 7, 391-393	4.6	
205	Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , <b>2018</b> , 5, e498	9.1	50
204	Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. <i>Journal of Neurology</i> , <b>2018</b> , 265, 1850-1859	5.5	27
203	Computerized posturography is more sensitive than clinical Romberg Test in detecting postural control impairment in minimally impaired Multiple Sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , <b>2017</b> , 14, 51-55	4	12
202	Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 308-315	3.2	7
201	Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 339-343	3.2	9
200	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , <b>2017</b> , 81, 729-739	9.4	26
199	Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 350-355	3.2	7

198	Italian national guidelines for the screening of gestational diabetes: Time for a critical appraisal?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2017</b> , 27, 717-722	4.5	9
197	A20 in Multiple Sclerosis and Parkinson@ Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?. <i>Neurotoxicity Research</i> , <b>2017</b> , 32, 1-7	4.3	14
196	Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients. <i>Journal of Immunological Methods</i> , <b>2017</b> , 445, 53-58	2.5	7
195	Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e317	9.1	48
194	High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. <i>Neurology and Therapy</i> , <b>2017</b> , 6, 145-152	4.6	20
193	Cerebrospinal fluid analysis and the determination of oligoclonal bands. <i>Neurological Sciences</i> , <b>2017</b> , 38, 217-224	3.5	19
192	Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). <i>Neurological Sciences</i> , <b>2017</b> , 38, 231-236	3.5	12
191	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , <b>2017</b> , 140, 2814-2819	11.2	38
190	A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-βa using RebiSmart: the FUTURE study. <i>Neurological Sciences</i> , <b>2017</b> , 38, 1999-2005	3.5	9
189	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. <i>Neurological Sciences</i> , <b>2017</b> , 38, 1849-1858	3.5	19
188	A Comprehensive Review on Copemyl. <i>Neurology and Therapy</i> , <b>2017</b> , 6, 161-173	4.6	6
187	Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients. <i>Clinical Immunology</i> , <b>2017</b> , 181, 83-88	9	14
186	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , <b>2017</b> , 2,	0	3
185	The Effectiveness of a Body-Affective Mindfulness Intervention for Multiple Sclerosis Patients with Depressive Symptoms: A Randomized Controlled Clinical Trial. <i>Frontiers in Psychology</i> , <b>2017</b> , 8, 2083	3.4	24
184	Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 321	8.4	16
183	The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice. <i>Cephalalgia</i> , <b>2016</b> , 36, 131-8	6.1	17
182	Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. <i>Neurological Sciences</i> , <b>2016</b> , 37, 2019-2023	3.5	1
181	The heritage of glatiramer acetate and its use in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , <b>2016</b> , 1,	0	8

180	A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , <b>2016</b> , 292, 34-9	3.5	20
179	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon $\beta$ therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1163-73 <sup>5</sup>		18
178	Cytokine profiles show heterogeneity of interferon- $\beta$ response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2016</b> , 3, e202	9.1	26
177	PML risk stratification using anti-JCV antibody index and L-selectin. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1048-60	5	57
176	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153466	3.7	20
175	Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual Subjects. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155268	3.7	8
174	Decline of Neuropsychological Abilities in a Large Sample of Patients with Multiple Sclerosis: A Two-Year Longitudinal Study. <i>Frontiers in Human Neuroscience</i> , <b>2016</b> , 10, 282	3.3	8
173	Anal sphincter dysfunction in multiple sclerosis: an observation manometric study. <i>Open Medicine (Poland)</i> , <b>2016</b> , 11, 509-517	2.2	9
172	Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study. <i>Multiple Sclerosis and Demyelinating Disorders</i> , <b>2016</b> , 1,	0	2
171	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1005-15	5.5	157
170	Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson $\otimes$ and Alzheimer $\otimes$ Disease Patients. <i>Neurotoxicity Research</i> , <b>2016</b> , 30, 338-44	4.3	35
169	The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial. <i>BMC Neurology</i> , <b>2016</b> , 16, 7	3.1	12
168	Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1713-22	5	20
167	Evaluation of the impact of neutralizing antibodies on IFN $\beta$ response. <i>Clinica Chimica Acta</i> , <b>2015</b> , 449, 31-6	6.2	14
166	Biological monitoring of IFN- $\beta$ therapy in Multiple Sclerosis. <i>Cytokine and Growth Factor Reviews</i> , <b>2015</b> , 26, 241-8	17.9	15
165	Acute confusional state in HaNDL syndrome (transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis). <i>Neurological Sciences</i> , <b>2015</b> , 36, 477-8	3.5	6
164	Quality of life and patient preferences: identification of subgroups of multiple sclerosis patients. <i>Quality of Life Research</i> , <b>2015</b> , 24, 2173-82	3.7	12
163	Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor- $\alpha$ therapy. <i>Neurology and Therapy</i> , <b>2015</b> , 4, 53-60	4.6	4

162	Anti-inflammatory genes associated with multiple sclerosis: a gene expression study. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 279, 75-8	3.5	12
161	Nurr1 reduction influences the onset of chronic EAE in mice. <i>Inflammation Research</i> , <b>2015</b> , 64, 841-4	7.2	18
160	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , <b>2015</b> , 138, 3275-86	11.2	63
159	No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 585-7	6	21
158	Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129291	3.7	20
157	Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers. <i>Neurology and Therapy</i> , <b>2015</b> , 4, 147-57	4.6	36
156	Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. <i>Journal of Neuroinflammation</i> , <b>2015</b> , 12, 146	10.1	19
155	Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , <b>2015</b> , 12, 132	10.1	15
154	Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , <b>2014</b> , 35, 307-16	3.5	28
153	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , <b>2014</b> , 83, 1210-6	6.5	26
152	Effects of isoxazolo-pyridinone 7e, a potent activator of the Nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mice. <i>PLoS ONE</i> , <b>2014</b> , 9, e108791	3.7	24
151	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 577-87	5	35
150	CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept study. <i>Journal of Neuroimmunology</i> , <b>2014</b> , 277, 127-33	3.5	5
149	Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 889-91	5	3
148	Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy@ Adherence, Hospital Reliability@ Perception, and Services Provided Quality. <i>Multiple Sclerosis International</i> , <b>2014</b> , 2014, 752318	1.1	12
147	A new neurophysiological approach to assess central motor conduction damage to proximal and distal muscles of lower limbs. <i>Clinical Neurophysiology</i> , <b>2014</b> , 125, 133-41	4.3	5
146	Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2014</b> , 272, 99-102	3.5	20
145	Prevalence and significant determinants of post-traumatic stress disorder in a large sample of patients with multiple sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , <b>2013</b> , 20, 240-6	2	20

144	Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo study): rationale, design, and methodology. <i>Neurological Sciences</i> , <b>2013</b> , 34, 1297-307	3.5	14
143	The role of fatigue in the associations between exercise and psychological health in Multiple Sclerosis: Direct and indirect effects. <i>Mental Health and Physical Activity</i> , <b>2013</b> , 6, 87-94	5	10
142	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1508-17	5	35
141	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1802-9	5	99
140	Presence and significant determinants of cognitive impairment in a large sample of patients with multiple sclerosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e69820	3.7	36
139	Classification of individuals based on ex-vivo glatiramer acetate-induced interferon- $\gamma$ and interleukin-4 response. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1484-92	5	2
138	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 143-52	5	186
137	Recommendations to standardize preanalytical confounding factors in Alzheimer $\beta$ and Parkinson $\alpha$ disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 419-30	2.3	230
136	Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. <i>Journal of NeuroImmune Pharmacology</i> , <b>2012</b> , 7, 665-72	6.9	28
135	Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2012</b> , 13, 183	2.8	13
134	Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. <i>PLoS ONE</i> , <b>2012</b> , 7, e38896	3.7	18
133	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 835-42	5	95
132	Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation. <i>Neurological Sciences</i> , <b>2012</b> , 33, 863-7	3.5	8
131	Non-invasive ventilation in amyotrophic lateral sclerosis: a 10 year population based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, 377-81	5.5	59
130	A methodological reappraisal of non invasive high voltage electrical stimulation of lumbosacral nerve roots. <i>Clinical Neurophysiology</i> , <b>2011</b> , 122, 2071-80	4.3	28
129	Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis. <i>Archives of Neurology</i> , <b>2011</b> , 68, 879-88		38
128	Detection of Neutralizing Antibodies against Interferon Beta by Real-Time RT-PCR <b>2011</b> , 157-174		
127	One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. <i>Journal of Neurology</i> , <b>2011</b> , 258, 895-903	5.5	22



126	Three years of experience: the Italian registry and safety data update. <i>Neurological Sciences</i> , <b>2011</b> , 31 Suppl 3, 295-7	3.5	25
125	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. <i>Neurological Sciences</i> , <b>2011</b> , 32, 351-8	3.5	15
124	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. <i>Neurological Sciences</i> , <b>2011</b> , 32, 1223-31	3.5	33
123	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , <b>2011</b> , 77, 1887-95	6.5	59
122	Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. <i>PLoS ONE</i> , <b>2010</b> , 5, e8962	3.7	59
121	A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2010</b> , 81, 26-30	5.5	34
120	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 402-15	59.2	1686
119	Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. <i>Archives of Neurology</i> , <b>2010</b> , 67, 402-7		26
118	Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2010</b> , 81, 1141-3	5.5	69
117	Progressive multifocal leukoencephalopathy in Good@ syndrome. <i>International Journal of Infectious Diseases</i> , <b>2010</b> , 14 Suppl 3, e367-8	10.5	3
116	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 1360-6	5	52
115	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 68-77	5	75
114	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , <b>2010</b> , 31, 467-70	3.5	36
113	Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. <i>Lancet Neurology, The</i> , <b>2010</b> , 9, 740-50	24.1	164
112	Acute-phase proteins investigation based on lectins affinity capture prior to 2-DE separation: application to serum from multiple sclerosis patients. <i>Electrophoresis</i> , <b>2010</b> , 31, 2882-93	3.6	19
111	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 620-6	5	44
110	In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 789-94	5	21
109	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 779-88	5	141

108	Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 212-8	5	19
107	Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. <i>Journal of Neuroimmunology</i> , <b>2009</b> , 217, 74-9	3.5	29
106	Corpus callosum damage and cognitive dysfunction in benign MS. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 2656-66	6.5	82
105	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , <b>2009</b> , 30, 193-9	3.5	58
104	The pharmacovigilance program on natalizumab in Italy: 2 years of experience. <i>Neurological Sciences</i> , <b>2009</b> , 30 Suppl 2, S163-5	3.5	14
103	Implications of neutralising antibodies on therapeutic efficacy. <i>Journal of the Neurological Sciences</i> , <b>2009</b> , 277 Suppl 1, S29-32	3.2	15
102	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1503-11	4.0	475
101	Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. <i>Journal of Immunological Methods</i> , <b>2008</b> , 336, 119-26	2.5	18
100	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet, The</i> , <b>2008</b> , 371, 2085-92	4.0	236
99	Cognitive impairment and structural brain damage in benign multiple sclerosis. <i>Neurology</i> , <b>2008</b> , 71, 1526-6	6.5	79
98	A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis. <i>Archives of Neurology</i> , <b>2008</b> , 65, 1223-30	6.5	54
97	Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , <b>2008</b> , 70, 1891-7	6.5	209
96	Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. <i>Neurology</i> , <b>2008</b> , 71, 1940-7	6.5	33
95	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 1225-33	5	58
94	Predictive markers for response to interferon therapy in patients with multiple sclerosis. <i>Neurology</i> , <b>2008</b> , 70, 1119-27	6.5	78
93	Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. <i>Neurological Sciences</i> , <b>2008</b> , 29, 185-7	3.5	10
92	Interferon-beta responders and non-responders. A biological approach. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 2, S216-7	3.5	17
91	Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 2, S227-9	3.5	8

90	Clinical Aspects of Immunogenicity to Biopharmaceuticals <b>2008</b> , 27-56		7
89	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. <i>Journal of International Medical Research</i> , <b>2008</b> , 36, 204-8; author reply 208-10	1.4	2
88	Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. <i>Journal of Immunological Methods</i> , <b>2007</b> , 321, 19-31	2.5	62
87	Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. <i>Journal of Neuroimmunology</i> , <b>2007</b> , 192, 198-205	3.5	21
86	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , <b>2007</b> , 254, 827-37	5.5	45
85	Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. <i>Neurological Sciences</i> , <b>2007</b> , 28, 127-32	3.5	49
84	Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). <i>Neurological Sciences</i> , <b>2007</b> , 28, 209-11	3.5	51
83	In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. <i>Brain</i> , <b>2007</b> , 130, 2211-9	11.2	130
82	Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i> , <b>2007</b> , 69, 1552; author reply 1553	6.5	6
81	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. <i>Multiple Sclerosis Journal</i> , <b>2007</b> , 13, 1068-70	5	45
80	Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2007</b> , 78, 1349-53	5.5	102
79	Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. <i>Multiple Sclerosis Journal</i> , <b>2007</b> , 13, 490-501	5	69
78	Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. <i>Brain</i> , <b>2006</b> , 129, 2628-34	11.2	111
77	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2006</b> , 12, 578-85	5	26
76	High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. <i>European Journal of Endocrinology</i> , <b>2006</b> , 154, 745-51	6.5	34
75	Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. <i>Multiple Sclerosis Journal</i> , <b>2006</b> , 12, 47-57	5	86
74	Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2006</b> , 12, 738-46	5	17
73	Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. <i>NeuroImage</i> , <b>2005</b> , 24, 1139-46	7.9	99

72	Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. <i>Journal of the Neurological Sciences</i> , <b>2005</b> , 237, 5-11	3.2	13
71	Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2005</b> , 158, 195-203	3.5	51
70	Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. <i>Neurological Sciences</i> , <b>2005</b> , 26 Suppl 4, S183-6	3.5	52
69	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. <i>Neurological Sciences</i> , <b>2005</b> , 26 Suppl 4, S200-3	3.5	15
68	Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. <i>Neurological Sciences</i> , <b>2005</b> , 26 Suppl 4, S213-4	3.5	10
67	The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. <i>Neurology</i> , <b>2004</b> , 63, 919-21	6.5	221
66	Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. <i>Brain</i> , <b>2004</b> , 127, 259-68	11.2	57
65	Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2004</b> , 75, 1294-9	5.5	48
64	Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. <i>Neurology</i> , <b>2004</b> , 62, 2031-7	6.5	141
63	Risk of cancer in patients with Guillain-Barré syndrome (GBS). A population-based study. <i>Journal of Neurology</i> , <b>2004</b> , 251, 321-6	5.5	69
62	Immunogenicity of interferon beta: differences among products. <i>Journal of Neurology</i> , <b>2004</b> , 251 Suppl 2, II15-II24	5.5	53
61	Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. <i>Journal of Neurology</i> , <b>2004</b> , 251 Suppl 2, II31-9	5.5	14
60	Cerebrospinal fluid findings in Devic's neuromyelitis optica. <i>Neurological Sciences</i> , <b>2004</b> , 25 Suppl 4, S368-70	3.5	30
59	Italian studies on early-onset multiple sclerosis: the present and the future. <i>Neurological Sciences</i> , <b>2004</b> , 25 Suppl 4, S346-9	3.5	17
58	Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis?. <i>Acta Neurologica Scandinavica</i> , <b>2004</b> , 109, 61-5	3.8	12
57	Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. <i>Molecular Diagnosis and Therapy</i> , <b>2004</b> , 8, 185-94		2
56	Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 4923-8	5.6	114
55	Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. <i>Current Opinion in Neurology</i> , <b>2004</b> , 17, 241-6	7.1	25

54	Comparison of Three PCR Assays for the Evaluation of Interferon-?? Biological Activity in Patients with Multiple Sclerosis. <i>Molecular Diagnosis and Therapy</i> , <b>2004</b> , 8, 185-194		13
53	Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse. <i>Neurological Sciences</i> , <b>2003</b> , 24, 130-3	3.5	22
52	Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. <i>Neurology</i> , <b>2003</b> , 60, 634-9	6.5	160
51	Guillain-Barré Syndrome: a prospective, population-based incidence and outcome survey. <i>Neurology</i> , <b>2003</b> , 60, 1146-50	6.5	161
50	Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b. <i>Multiple Sclerosis Journal</i> , <b>2003</b> , 9, 420-3	5	10
49	Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). <i>Neurology</i> , <b>2003</b> , 61, S24-6	6.5	51
48	Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients. <i>Journal of Immunological Methods</i> , <b>2002</b> , 262, 187-90	2.5	16
47	Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2002</b> , 73, 148-53	5.5	98
46	Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. <i>Archives of Neurology</i> , <b>2002</b> , 59, 1406-12		148
45	Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. <i>Journal of Immunological Methods</i> , <b>2001</b> , 256, 141-52	2.5	77
44	In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. <i>Brain</i> , <b>2001</b> , 124, 2540-9	11.2	129
43	Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. <i>European Cytokine Network</i> , <b>2001</b> , 12, 56-61	3.3	65
42	Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. <i>Immunopharmacology</i> , <b>2000</b> , 48, 95-100		90
41	Quantitative PCR reveals increased levels of tumor necrosis factor-alpha mRNA in peripheral blood mononuclear cells of multiple sclerosis patients during relapses. <i>Journal of Interferon and Cytokine Research</i> , <b>1999</b> , 19, 575-81	3.5	10
40	Transforming growth factor beta1 (TGFbeta1) mRNA level correlates with magnetic resonance imaging disease activity in multiple sclerosis patients. <i>Neuroscience Letters</i> , <b>1999</b> , 263, 21-4	3.3	21
39	5D4 keratan sulfate epitope identifies a subset of ramified microglia in normal central nervous system parenchyma. <i>Journal of Neuroimmunology</i> , <b>1998</b> , 85, 69-77	3.5	25
38	Morphological and biochemical investigations of mitral valve endocardiosis in pigs. <i>Research in Veterinary Science</i> , <b>1997</b> , 62, 121-5	2.5	12
37	Immunohistochemical mapping of perineuronal nets containing chondroitin unsulfated proteoglycan in the rat central nervous system. <i>Cell and Tissue Research</i> , <b>1996</b> , 283, 283-95	4.2	60

36	Disappearance of the Vicia villosa-positivity from the perineuronal net containing chondroitin proteoglycan after chondroitinase digestion. <i>Brain Research</i> , <b>1995</b> , 673, 344-8	3-7	9
35	Keratan sulphate is a marker of differentiation of ramified microglia. <i>Developmental Brain Research</i> , <b>1995</b> , 86, 233-41		17
34	Monoclonal antibodies to keratan sulfate immunolocalize ramified microglia in paraffin and cryostat sections of rat brain. <i>Journal of Histochemistry and Cytochemistry</i> , <b>1993</b> , 41, 481-7	3-4	42
33	Congenital muscular dystrophy associated with familial junctional epidermolysis bullosa letalis. <i>European Neurology</i> , <b>1993</b> , 33, 454-60	2-1	17
32	Selective expression of the Met/HGF receptor in human central nervous system microglia. <i>Oncogene</i> , <b>1993</b> , 8, 219-22	9-2	56
31	Chondroitin sulfate proteoglycan surrounds a subset of human and rat CNS neurons. <i>Journal of Neuroscience Research</i> , <b>1991</b> , 29, 225-34	4-4	74
30	Differential distribution and modulation of expression of alpha 1/beta 1 integrin on human endothelial cells. <i>Journal of Cell Biology</i> , <b>1991</b> , 114, 855-63	7-3	155
29	Chondroitin 4-sulfate proteoglycan forms an extracellular network in human and rat central nervous system. <i>Journal of the Neurological Sciences</i> , <b>1990</b> , 100, 113-23	3-2	59
28	Extracellular matrix of cultured glial cells: selective expression of chondroitin 4-sulfate by type-2 astrocytes and their progenitors. <i>Experimental Cell Research</i> , <b>1990</b> , 187, 211-23	4-2	48
27	Biochemical, histochemical and immunohistochemical study of glycosaminoglycans in human meningiomas. <i>Basic and Applied Histochemistry</i> , <b>1989</b> , 33, 239-49		1
26	Glutamate dehydrogenase (GDH) deficiency in different types of progressive hereditary cerebellar ataxia. <i>Acta Neurologica Scandinavica</i> , <b>1988</b> , 78, 394-400	3-8	7
25	Chondroitin, chondroitin 6-sulphate, chondroitin 4-sulphate and dermatan sulphate proteoglycans in normal and pathological human muscle. <i>Journal of the Neurological Sciences</i> , <b>1987</b> , 81, 247-59	3-2	9
24	The proteoglycan chondroitin sulfate is present in a subpopulation of cultured astrocytes and in their precursors. <i>Developmental Biology</i> , <b>1987</b> , 123, 282-5	3-1	75
23	Immunohistochemical study of chondroitin sulfate in human gliomas. <i>Acta Neuropathologica</i> , <b>1986</b> , 72, 189-96	14-3	13
22	Glycosaminoglycan changes in human gliomas. A biochemical study. <i>Journal of Neuro-Oncology</i> , <b>1986</b> , 4, 43-8	4-8	23
21	Immunohistochemical localization of chondroitin sulfate in normal and pathological human muscle. <i>Journal of the Neurological Sciences</i> , <b>1986</b> , 73, 233-44	3-2	38
20	Quantitation of nanogram amounts of glycosaminoglycans in samples containing proteins by a new densitometric method. <i>Electrophoresis</i> , <b>1985</b> , 6, 35-38	3-6	4
19	Induction of brain tumors by transplacental enu: Correlation between neurocytogenesis and tumor development. <i>International Journal of Developmental Neuroscience</i> , <b>1985</b> , 3, 431-431	2-7	

18	Cellulose acetate electrophoresis of glycosaminoglycans in the central nervous system. <i>Electrophoresis</i> , <b>1984</b> , 5, 97-101	3.6	10
17	Collagenase in the immunohistochemical demonstration of laminin, fibronectin and factor VIII/RAG in nervous tissue after fixation. <i>Histochemistry</i> , <b>1984</b> , 80, 157-63		42
16	Biochemical and histochemical evaluation of glycosaminoglycans in brain tumors induced in rats by nitrosourea derivatives. <i>Journal of Neuro-Oncology</i> , <b>1983</b> , 1, 299-306	4.8	8
15	Laminin and fibronectin distribution in normal and pathological human muscle. <i>Journal of the Neurological Sciences</i> , <b>1983</b> , 60, 377-82	3.2	24
14	Glycosaminoglycans (GAGs) in human cerebral tumors. Part 1. Biochemical findings. <i>Acta Neuropathologica</i> , <b>1982</b> , 58, 115-9	14.3	18
13	Glycosaminoglycans in human cerebral tumors. Part II. Histochemical findings and correlations. <i>Acta Neuropathologica</i> , <b>1982</b> , 57, 299-305	14.3	17
12	Osteomalacic myopathy in a case of diffuse nodular lipomatosis of the small bowel. <i>Acta Neurologica Belgica</i> , <b>1982</b> , 82, 65-71	1.5	4
11	Ineffectiveness of allopurinol in Duchenne muscular dystrophy. <i>Muscle and Nerve</i> , <b>1981</b> , 4, 176-8	3.4	7
10	Myoglobinuria: presentation of personal cases and review of the literature. <i>Italian Journal of Neurological Sciences</i> , <b>1981</b> , 2, 275-82		3
9	Epidemiology of Duchenne muscular dystrophy in the province of Turin. <i>Italian Journal of Neurological Sciences</i> , <b>1981</b> , 2, 81-4		6
8	On the Nature of the So-Called Monstrocellular Sarcoma of the Brain. <i>Neurosurgery</i> , <b>1980</b> , 6, 391-397	3.2	3
7	Motor neuron disease following poliomyelitis. Bioptic study of five cases. <i>European Neurology</i> , <b>1980</b> , 19, 414-8	2.1	5
6	On the nature of the so-called monstrocellular sarcoma of the brain. <i>Neurosurgery</i> , <b>1980</b> , 6, 391-7	3.2	8
5	Mitochondrial abnormalities of late motor neuron degeneration following poliomyelitis and other neurogenic muscular atrophies. <i>Journal of Neurology</i> , <b>1979</b> , 221, 193-201	5.5	6
4	Acute muscle necrosis after chronic overdosage of phenformin and fenfluramine. <i>Muscle and Nerve</i> , <b>1978</b> , 1, 245-7	3.4	10
3	Two-dimensional immunoelectrophoresis of unconcentrated cerebrospinal fluid. <i>Journal of the Neurological Sciences</i> , <b>1978</b> , 37, 199-203	3.2	1
2	Histochemical and ultrastructural findings in a case of centronuclear myopathy. <i>European Neurology</i> , <b>1978</b> , 17, 327-32	2.1	6
1	Sporadic oculopharyngeal myopathy with abnormal mitochondria. <i>Acta Neurologica Belgica</i> , <b>1978</b> , 78, 373-82	1.5	4

